AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy

GLEN BURNIE, Md., July 27, 2020 -- (Healthcare Sales & Marketing Network) -- AxoProtego Therapeutics (AxoProtego) has announced that it has licensed a novel investigational therapy for patients with chemotherapy-induced peripheral neuropathy (CIPN). Curr... Biopharmaceuticals, Oncology, Neurology, Licensing AxoProtego Therapeutics, chemotherapy-induced peripheral neuropathy

Source: HSMN NewsFeed - July 27, 2020 Category: Pharmaceuticals Source Type: news